Macrophage Therapeutics is developing novel immunotherapeutics that target activated macrophages with very high specificity. The compounds are synthesized using the Manocept platform technology which is the backbone technology of an FDA-approved product. Government grants have been awarded to further study the application of Manocept across multiple disease states.
Early foundational studies are validating the potential therapeutic applications of the technology and will be published in the near future in leading scientific journals. We will continue to conduct studies to demonstrate the safety profile and activity of our innovative approach, and are excited by the breadth of opportunities.
We are conducting a number of pre-clinical trials on our Manocept-derived lead compounds in various in vivo animal models, which are yielding promising results.
|Study Indications Oncology:||Animal Model:||Summary of Results (for completed studies):|
|Kaposi’s Sarcoma/HIV||SCID-hu Thy/Liv mouse model|
|Breast Cancer||Mouse Mammary Tumors (4T1 cells) in Balb/c mice|
|Melanoma||BRAFi and BRAF/MEKi resistant patient-derived xenograft (PDX) models|
|HER-2 Breast Cancer||H2N113 tumors in BALB/c mice|
|Other Solid Tumors (CRC, GBM, Lung, H&N)||Human PDX xenograft mouse models|
|Rheumatoid Arthritis||Anti-cartilage Ab/E. coli LPS induced RA in Dba1 mice|
|Alzheimer’s Disease||Transgenic CVN-AD mouse model|
|Multiple Sclerosis||Cuprizone-induced demyelination mouse model|
|Globoid Cell Leukodystrophy (Krabbe disease)||Twitcher mouse model of GLD|
|Tuberculosis||M.Tb infected BALB/c and BALB/c SCID mice|